Genmab — November 2017
-
Durable clinical responses in heavily pretreated patients with relapsed/refractory multiple myeloma: Updated results from a multicenter study of bb2121 anti-BCMA CAR T cell therapy (Oral Abstract #740)
Presenter: Jesus Berdeja, M.D., Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN
Date & Time: Monday, December 11 at 3:00 pm
Location: Bldg C, Lvl 1, Hall C1 -
@Vitus . Nu er genmab jo steget en siden 2013 fra ca. 200 til 1300 saa at den tager en puster I 2017 og maaske kun stiger 20% er vel ikke verdens undergang. Jeg er sikker paa der sker lidt med kursen naar 1line blir godkendt og saa er der jo lige resten a pipelinen. P.t holder Jan's guiding for 2017 og det kommer den nok ogsaa til at Goethe
-
@stockbull : 8,6% ÅTD, så hvis du mener "kun 20 %", skal der snart ske noget....

-
Stok Bull: Jeg skriver jo heller ikke at det er verdens undergang, at aktien ikke stiger p.t. (Men falder).....jeg forsøger bare at forklare de chatter, der vil snakke den op, at det kan man heldigvis ikke. Der skal resultater på bordet.... den har jo været snakket op i 2017, så realismen har heldigvis fået den på plads !
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
